315 related articles for article (PubMed ID: 29860848)
1. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
Jindal V
Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
3. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
5. Immune-based therapies for metastatic prostate cancer: an update.
Hossain MK; Nahar K; Donkor O; Apostolopoulos V
Immunotherapy; 2018 Feb; 10(4):283-298. PubMed ID: 29421982
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for prostate cancer: False promises or true hope?
Rekoske BT; McNeel DG
Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer immunotherapy: the path forward.
Madan RA; Gulley JL
Curr Opin Support Palliat Care; 2017 Sep; 11(3):225-230. PubMed ID: 28644303
[TBL] [Abstract][Full Text] [Related]
8. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
10. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
[TBL] [Abstract][Full Text] [Related]
12. A New Era of Immunotherapy in Prostate Cancer.
Pizzola C; Rizvi SM; Joshi M
Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
[TBL] [Abstract][Full Text] [Related]
13. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options.
Chakravarty D; Huang L; Kahn M; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4):487-510. PubMed ID: 33008499
[TBL] [Abstract][Full Text] [Related]
15. Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer.
Schatten H
Adv Exp Med Biol; 2018; 1096():185-194. PubMed ID: 30324354
[TBL] [Abstract][Full Text] [Related]
16. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
17. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.
Paller CJ; Antonarakis ES
Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
19. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
20. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
Antonarakis ES; Drake CG
Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]